LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
82.07
+0.41 (+0.50%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close81.66
Open81.49
Bid0.00 x 900
Ask0.00 x 1300
Day's Range81.49 - 82.29
52 Week Range73.69 - 89.09
Volume4,002,281
Avg. Volume4,281,851
Market Cap83.767B
Beta0.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.25 (2.77%)
Ex-Dividend Date2018-02-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    Possible Shift in Medicare Drug Organization May Give Pharma Heartburn

    A possible reshaping of how some Medicare drugs are paid for has drug companies feeling sick. Health and Human Services Secretary Alex Azar's plan to consolidate at least some Part B prescription drugs under Part D could cost pharmaceutical companies real money since while there are no price negotiations under Part B, Part D includes discount, rebates and negotiating tools. Part B drugs are those that are administered in a doctor's office, clinic, hospital or someplace beyond the patient's home.

  • Eli Lilly’s Business Segments in Q1 2018
    Market Realist2 days ago

    Eli Lilly’s Business Segments in Q1 2018

    Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health. The above chart compares the segment-wise quarterly revenues for Eli Lilly since the first quarter of 2017. The US markets reported a 10% growth in revenues in the first quarter, driven by an 8% positive impact of prices and a 2% growth in volumes.

  • Eli Lilly’s Revenue Trend in Q1 2018
    Market Realist2 days ago

    Eli Lilly’s Revenue Trend in Q1 2018

    Eli Lilly’s (LLY) revenues surpassed Wall Street analysts’ estimates and reported a 9% growth to $5.7 billion for the first quarter. The above graph compares Eli Lilly’s quarterly revenues since the first quarter of 2017 and includes estimates for this year’s second quarter. Wall Street analysts estimate revenues of $6 billion for the second quarter, which would be a 3.7% growth compared to $5.8 billion in the second quarter of 2017.

  • Eli Lilly’s Valuation on May 17
    Market Realist3 days ago

    Eli Lilly’s Valuation on May 17

    Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks3 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • TheStreet.com3 days ago

    Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

    said late Thursday, May 17, they have obtained approval from the U.S. Food and Drug Administration for Aimovig, a migraine prevention drug for adults. The drug is the first treatment green-lighted by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor, thought to play a key role in the disease. "We believe Amgen will benefit significantly from its first mover advantage and ultimately retain 35-40% market share long term," Leerink Partners LLC analyst Geoffrey C. Porges wrote in a note on Friday.

  • AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
    Zacks3 days ago

    AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

    AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

  • Reuters3 days ago

    U.S. FDA approves Amgen migraine drug, price set at $6900/yr

    The U.S. Food and Drug Administration on Thursday approved Amgen Inc's drug Aimovig for the prevention of migraine headaches in adults. The drug, given monthly by self injection, will have a list price of $6,900 a year, or $575 a month, the company said. Any discounts or rebates will depend on negotiations with health plans, said Amgen spokeswoman Kristen Davis.

  • Exelixis Is Expected to Report a Robust Revenue Rise in 2018
    Market Realist4 days ago

    Exelixis Is Expected to Report a Robust Revenue Rise in 2018

    The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.

  • Teva’s Fiscal Guidance: Confidence in Its Growth
    Market Realist4 days ago

    Teva’s Fiscal Guidance: Confidence in Its Growth

    Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.

  • Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
    Zacks5 days ago

    Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

    Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

  • Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline
    Zacks6 days ago

    Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline

    Eli Lilly (LLY) to buy an early phase oncology asset, AK-01, from AurKa Pharma to expand its oncology pipeline.

  • An Update on Teva’s Highly Anticipated Migraine Drug
    Market Realist6 days ago

    An Update on Teva’s Highly Anticipated Migraine Drug

    During Teva’s (TEVA) 1Q18 earnings release on May 3, the company provided an update on the approval and launch of its anti-CGRP (calcitonin gene-related peptide) monoclonal antibody Fremanezumab, a preventive migraine treatment. The company stated that it now doesn’t expect to get FDA (U.S. Food and Drug Administration) approval for Fremanezumab in mid-June as it had earlier estimated. The reason that Teva doesn’t expect approval in June is that Celltrion, which is Teva’s API (active pharmaceutical ingredients) supplier of Fremanezumab, got a warning letter from the FDA in 2017.

  • Star Kleiner Perkins VC may be launching her own firm
    American City Business Journals6 days ago

    Star Kleiner Perkins VC may be launching her own firm

    The high-profile departure would be the latest in a string of exits of top investors in recent years from one of Silicon Valley's oldest and most successful venture firms.

  • An Overview of Valeant Pharmaceuticals’ Performance in 1Q18
    Market Realist6 days ago

    An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

    In 1Q18, Valeant Pharmaceuticals’ (VRX) revenues witnessed an ~5.0% decline to reach $2.0 billion. Valeant Pharmaceuticals had an operating loss and net loss of ~$2.3 billion and ~$2.7 billion, respectively, in 1Q18. To learn more about its 1Q18 financial data, please read How Valeant Pharmaceuticals Performed in 1Q18.

  • MarketWatch6 days ago

    Eli Lilly's cluster-headache treatment passes phase 3 test

    Eli Lilly & Co. said Tuesday a phase 3 trial of galcanezumab for the treatment of episodic cluster headaches met its primary endpoint, and also achieved its secondary endpoint. Lilly said it is now working with regulatory agencies to determine the best path forward for galcanezumab. "Cluster headache can be difficult to evaluate in clinical studies, which has contributed to few available treatment options for cluster headache, often considered the most severe pain one can experience," said Christi Shaw, president of Lilly Bio-Medicines.

  • Reuters6 days ago

    Lilly's migraine drug meets main goal in cluster headache trial

    Eli Lilly and Co said on Tuesday that patients with episodic cluster headache attacks had reduced symptoms when treated with its experimental migraine drug galcanezumab compared to those treated with a placebo. Patients with episodic cluster headache treated with a 300 mg dose of galcanezumab experienced an average of 8.7 fewer headache attacks per week over a three-week period. Patients who participated in the trial had a baseline average of 17.5 cluster headache attacks per week.

  • Reuters7 days ago

    Lilly to buy cancer drug developer AurKa Pharma

    Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors. The deal is Lilly's second in less than a week that aims to broaden its portfolio of lucrative cancer drugs. On Thursday, Lilly said it would buy Armo BioSciences Inc for about $1.6 billion.

  • Forbes7 days ago

    Eli Lilly Takes $7M Gamble On Global Health Working... In Indiana

    Last week, Chairman, President and CEO of Eli Lilly and Company (LLY) Dave Ricks managed to merge powerful ideas about the context of health, global research initiatives and job competition in the state of Indiana into one talk. What Mr. Ricks ultimately proposed to do was take ideas that Lilly had learned in emerging markets – often referred to as developing countries – and apply those to neighborhoods in the U.S. with similar economic and health characteristics. This is especially true for diabetes, a group of diseases that affect how your body uses blood sugar, and is an important source of energy for cells.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool9 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can the momentum keep going for these sizzling-hot biotech stocks?

  • Trump's prescription to reduce drug prices takes small steps
    Associated Press9 days ago

    Trump's prescription to reduce drug prices takes small steps

    WASHINGTON (AP) — President Donald Trump's long-promised plan to bring down drug prices would mostly spare the pharmaceutical industry he previously accused of "getting away with murder." Instead he focuses on private competition and more openness to reduce America's prescription pain.

  • Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
    Zacks9 days ago

    Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.

    Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.

  • The Wall Street Journal10 days ago

    [$$] Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion

    Eli Lilly and Co. is buying ARMO BioSciences Inc. for $1.6 billion, the latest investment in the hot area of immunotherapy cancer treatments. Immunotherapy, or immune-cell therapy, describes a range of treatments that harness a patient’s own immune system to target cancer. Lilly said Thursday it reached a deal to buy ARMO, which had an initial public offering in January, for $50 a share in cash, a 68% premium to its closing price Wednesday.

  • How Teva Performed in 1Q18
    Market Realist10 days ago

    How Teva Performed in 1Q18

    In fiscal 1Q18, Teva Pharmaceutical Industries (TEVA) reported GAAP (generally accepted accounting principles) EPS of $1.03, whereas the non-GAAP EPS came in at $0.94. Teva’s gross profits in fiscal 1Q18 fell YoY by ~18% to $2.7 billion. The decline was mainly due to the weak performance in the North America region due to the lower Copaxone sales and pricing pressure in its generics business.

  • Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates
    Zacks10 days ago

    Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

    Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.